Novadaq Technologies Inc.   Report issue

For profit Phase 3
Founded: Mississauga Canada (2000)
Status: Acquired by Stryker (2017)

Organization Overview

First Clinical Trial
2018
NCT03200704
First Marketed Drug
2018
indocyanine green (ic-green)
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

NOVADAQ TECH | Novadaq Technologies Inc.

Active Ingredients

Marketed Drugs (1)

indocyanine green (ic-green) (2018)

Drugs in Phase 3 Trials (1)

indocyanine green (ic-green) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1